At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
Pirtobrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LOXO-305 in Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating Pirtobrutinib for Healthy. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the safety and tolerability of pirtobrutinib and to look at the amount of the study drug, pirtobrutinib, that gets into the blood stream and how long it takes the body to get rid of it when given in healthy adult participants. For each participant, the total duration of the study will be 46 days, including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsLoxo Oncology, Inc.
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
Primary CompletionDec 2020
First PostedDec 2023
TodayJul 2026
First PostedDec 26, 2023
Enrollment StartAug 14, 2020
Primary CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.5 years ago
Interventions
Pirtobrutinibdrug
Administered orally.